Search

Your search keyword '"Shigenori Kadowaki"' showing total 256 results

Search Constraints

Start Over You searched for: Author "Shigenori Kadowaki" Remove constraint Author: "Shigenori Kadowaki"
256 results on '"Shigenori Kadowaki"'

Search Results

151. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma

152. Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma

153. Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab + Irinotecan

154. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis

155. A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin

156. The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer

157. Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab

158. A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer

159. Impact of adding ramucirumab to paclitaxel in patients with advanced gastric cancer according to the level of ascites: A multicenter retrospective study

160. The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced esophageal cancer

161. A randomized phase II study to assess trastuzumab beyond progression in HER2-positive advanced gastric cancer: WJOG7112G

162. A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX)

163. An exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for peritoneal disseminated gastric cancer patients with inadequate oral intake

164. Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013)

165. A prospective survey of comprehensive score for financial toxicity (COST) in Japanese cancer patients

166. Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC)

167. Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: A multicenter retrospective study

168. Efficacy of cytotoxic agents after progression of anti-PD-(L)1 antibody for pretreated metastatic gastric cancer

169. A triplet combination with irinotecan, oxaliplatin, continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: A phase 1 dose finding study

170. Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer

171. Ease of early gastric cancer demarcation recognition: A comparison of four magnifying endoscopy methods

172. Systemic Chemotherapy with Cisplatin Plus 5-FU (PF) for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Efficacy and Safety of a Lower Dose of PF (80/800) at a Single Institution in Japan

173. A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer

174. [A questionnaire survey on QOL and toxicity in colorectal cancer survivors who received adjuvant chemotherapy]

175. Phase 1b study of first-line Ramucirumab + Platinum + Fluoropyrimidine in Japanese Patients with advanced gastric cancer

176. PD-L1 immunohistochemistry (IHC) by three different assays and molecular profiling in tissue microarray (TMA) of gastric cancer

177. Analysis of efficacy and prognostic factors in second-line chemotherapy for BRAF V600E mutant metastatic colorectal cancer

178. Risk of second malignancies after definitive therapy for esophageal cancer: A competing risk analysis

179. Abstract CT096: Phase 1b study of ramucirumab (RAM) in combination with fluoropyrimidine and platinum-based agents in Japanese patients (pts) with metastatic gastric/gastroesophageal junction adenocarcinoma (mGC)

180. Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy

181. Peritoneum metastasis (PM) as a prognostic factor in metastatic gastric cancer (MGC) treated with anti-PD-1/PD-L1 monotherapy

182. The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan, GI-screen: Efficient identification of cancer genome alterations in advanced gastric cancer

183. Exploratory study of intraperitoneal paclitaxel plus mFOLFOX6 for gastric cancer patients with peritoneal metastasis and inadequate oral intake

184. Efficacy of bevacizumab in combination with doublet chemotherapy as first-line therapy in metastatic colorectal cancer according to KRAS status

185. Impact of sarcopenia on survival outcomes in patients (pts) with metastatic gastric cancer (mGC)

186. Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months

187. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients

188. Aggressive neoplastic plasma cell growth with MLL gene rearrangement after high-dose therapy with autologous stem cell support for multiple myeloma

189. CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy

190. Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment

192. Phase III study comparing intraperitoneal paclitaxel plus S-1/paclitaxel with S-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial

193. Phase I study of alternate-day administration of S-1, oral leucovorin, and bevacizumab for refractory metastatic colorectal cancer

194. The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and cancer-related genome alterations in advanced colorectal cancer (CRC)—GI-SCREEN 2013-01-CRC sub-study

195. Phase III study of intraperitoneal paclitaxel plus s-1/paclitaxel compared with s-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial

196. The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced non-colorectal (Non-CRC) gastrointestinal cancer

197. A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer

198. Effect of first-line molecular targeted agents on the efficacy of second-line bevacizumab-containing regimen for metastatic colorectal cancer

199. Survival outcome of metastatic adenocarcinoma of esophagogastric junction in the trastuzumab era

200. Establishment and validation of prognostic nomograms including HER2 status in metastatic gastric cancer

Catalog

Books, media, physical & digital resources